Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cue Biopharma Inc (NQ: CUE )

1.220 +0.130 (+11.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cue Biopharma Inc

< Previous 1 2 Next >
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Strategic Organizational Transition
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Proposed Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Proposed Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.